Whitehawk Therapeutics, Inc. WHWK
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
2.98
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $7.1M | -$20.6M | — | -$98.0M | $136.3M |
| 2024 | $26.0M | -$63.7M | — | -$61.2M | $52.5M |
| 2023 | $24.4M | -$65.8M | — | -$63.6M | $105.2M |
| 2022 | $15.2M | -$60.5M | — | -$50.1M | $158.4M |
| 2021 | $14.0M | -$110.1M | — | -$22.5M | $136.4M |
| 2020 | $14.0M | -$3.5M | — | -$12.7M | -$12.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Dugan Margaret | Chief Medical Officer | 2026-05-14 | Grant | 19,132 | $3.92 |
| BALL BRYAN | See remarks | 2026-05-14 | Grant | 51,020 | $3.92 |
| Giacobello Scott M. | CHIEF FINANCIAL OFFICER | 2026-05-14 | Grant | 38,265 | $3.92 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.98 (safe)
- Working capital / assets 0.892
- Retained earnings / assets -2.342
- EBIT / assets -0.758
- Equity / liabilities 9.388
Source: SEC EDGAR filings · CIK 0001422142 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.